{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+-+Placebo",
    "query": {
      "intervention": "Insulin - Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 600,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+-+Placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T01:15:39.462Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05456854",
      "title": "Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Disease"
      ],
      "interventions": [
        {
          "name": "Hyperglycemic Clamp",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Kisspeptin-10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2022-06-03",
      "completion_date": "2024-08-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05456854"
    },
    {
      "nct_id": "NCT04995978",
      "title": "Insulin Resistance and Androgen Deprivation Therapy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Pioglitazone 30 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "MALE",
        "summary": "18 Years to 85 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2021-12-01",
      "completion_date": "2023-01-18",
      "has_results": false,
      "last_update_posted_date": "2023-06-23",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04995978"
    },
    {
      "nct_id": "NCT01753674",
      "title": "The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "TA-65",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Connecticut",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "35 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2015-05-28",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "Storrs, Connecticut",
      "locations": [
        {
          "city": "Storrs",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01753674"
    },
    {
      "nct_id": "NCT01011868",
      "title": "Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773 placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 494,
      "start_date": "2009-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01011868"
    },
    {
      "nct_id": "NCT01781234",
      "title": "Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tobacco Abstinence Syndrome"
      ],
      "interventions": [
        {
          "name": "Intranasal Insulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ajna Hamidovic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 51,
      "start_date": "2013-08",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-12-10",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01781234"
    },
    {
      "nct_id": "NCT01158417",
      "title": "Resveratrol in Type2 Diabetes and Obesity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Obesity",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Resveratrol 40 mg oral three times a day",
          "type": "DRUG"
        },
        {
          "name": "Resveratrol 500 mg oral once daily.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-12",
      "completion_date": "2012-07-08",
      "has_results": false,
      "last_update_posted_date": "2022-11-09",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "Williamsville, New York",
      "locations": [
        {
          "city": "Williamsville",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158417"
    },
    {
      "nct_id": "NCT01375491",
      "title": "Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 39,
      "start_date": "2009-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2020-01-13",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375491"
    },
    {
      "nct_id": "NCT02959762",
      "title": "Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Insulin Resistance",
        "Obesity in Diabetes",
        "Nutritional and Metabolic Diseases",
        "Hyperlipidemia",
        "Hyperglycemia",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Placebo-Control",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-10",
      "completion_date": "2020-12-30",
      "has_results": false,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02959762"
    },
    {
      "nct_id": "NCT07756294",
      "title": "Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Insulin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-09",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07756294"
    },
    {
      "nct_id": "NCT00782795",
      "title": "Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pancreatitis",
        "Insulin Resistance",
        "Normal or Mildly Abnormal Stool Fat Levels"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2008-11",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2018-01-11",
      "last_synced_at": "2026-09-07T01:15:39.462Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782795"
    }
  ]
}